Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Breast Cancer | Research

Erianin inhibits the progression of triple-negative breast cancer by suppressing SRC-mediated cholesterol metabolism

Authors: Ming Li, Shiyao Kang, Xuming Deng, Huimin Li, Yuan Zhao, Wenru Tang, Miaomiao Sheng

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Triple-negative breast cancer (TNBC) is highly malignant and lacks effective biotherapeutic targets. The development of efficient anticancer drugs with low toxicity and few side effects is a hotspot in TNBC treatment research. Although erianin is known to have potent antitumor activity, its regulatory mechanism and target in TNBC have not been fully elucidated, hampering further drug development. This study showed that erianin can significantly inhibit TNBC cell proliferation and migration, promote cell apoptosis, and inhibit the growth of transplanted tumors in mice. Mechanistically, through network pharmacology analysis, molecular docking and cellular thermal shift assays, we preliminarily identified SRC as the cellular target of erianin. Erianin potently inhibited the expression of SRC, which mediated the anticancer effect of erianin in TNBC. Moreover, erianin can downregulate the expression of genes related to cholesterol synthesis and uptake by targeting SRC, interfering with cholesterol levels in TNBC, thereby inhibiting the progression of TNBC in vivo and in vitro. Taken together, our results suggest that erianin may inhibit the progression of TNBC by suppressing SRC-mediated cholesterol metabolism, and erianin has the great potential to be an effective treatment for TNBC patients.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.PubMedCrossRef
3.
Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–69.PubMedCrossRef
4.
Lee KL, Kuo YC, Ho YS, Huang YH. Triple-negative breast Cancer: current understanding and future therapeutic breakthrough Targeting Cancer Stemness. Cancers (Basel) 2019, 11(9).
5.
Geiger S, Cnossen JA, Horster S, DiGioia D, Heinemann V, Stemmler HJ. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005. Anticancer Drugs. 2011;22(9):933–9.PubMedCrossRef
6.
Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular classifications of Triple-negative breast Cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98.PubMedPubMedCentralCrossRef
7.
Hurley J, Reis IM, Rodgers SE, Gomez-Fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat. 2013;138(3):783–94.PubMedCrossRef
8.
Goto W, Kashiwagi S, Takada K, Asano Y, Takahashi K, Fujita H, Takashima T, Tomita S, Hirakawa K, Ohira M. Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. J Transl Med. 2018;16(1):307.PubMedPubMedCentralCrossRef
9.
Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell. 2010;17(4):348–61.PubMedPubMedCentralCrossRef
10.
Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27.PubMed
11.
12.
Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010;327(5961):46–50.PubMedCrossRef
13.
Giacomini I, Gianfanti F, Desbats MA, Orso G, Berretta M, Prayer-Galetti T, Ragazzi E, Cocetta V. Cholesterol metabolic reprogramming in Cancer and its pharmacological modulation as therapeutic strategy. Front Oncol. 2021;11:682911.PubMedPubMedCentralCrossRef
14.
15.
Zhu Q, Sheng Y, Li W, Wang J, Ma Y, Du B, Tang Y. Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits bladder cancer cell growth via the mitochondrial apoptosis and JNK pathways. Toxicol Appl Pharmacol. 2019;371:41–54.PubMedCrossRef
16.
Yang L, Hu Y, Zhou G, Chen Q, Song Z. Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways. Biosci Rep 2020, 40(7).
17.
Chen YT, Hsieh MJ, Chen PN, Weng CJ, Yang SF, Lin CW. Erianin induces apoptosis and autophagy in oral squamous cell carcinoma cells. Am J Chin Med. 2020;48(1):183–200.PubMedCrossRef
18.
Wang H, Zhang T, Sun W, Wang Z, Zuo D, Zhou Z, Li S, Xu J, Yin F, Hua Y, et al. Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis. 2016;7(6):e2247.PubMedPubMedCentralCrossRef
19.
Chen P, Wu Q, Feng J, Yan L, Sun Y, Liu S, Xiang Y, Zhang M, Pan T, Chen X, et al. Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis. Signal Transduct Target Ther. 2020;5(1):51.PubMedPubMedCentralCrossRef
20.
Sheng Y, Chen Y, Zeng Z, Wu W, Wang J, Ma Y, Lin Y, Zhang J, Huang Y, Li W, et al. Identification of Pyruvate Carboxylase as the Cellular Target of Natural bibenzyls with potent anticancer activity against Hepatocellular Carcinoma via metabolic reprogramming. J Med Chem. 2022;65(1):460–84.PubMedCrossRef
21.
Sun J, Fu X, Wang Y, Liu Y, Zhang Y, Hao T, Hu X. Erianin inhibits the proliferation of T47D cells by inhibiting cell cycles, inducing apoptosis and suppressing migration. Am J Transl Res. 2016;8(7):3077–86.PubMedPubMedCentral
22.
Liu Z, Huang L, Sun L, Nie H, Liang Y, Huang J, Wu F, Hu X. Ecust004 suppresses breast Cancer Cell Growth, Invasion, and Migration via EMT regulation. Drug Des Devel Ther. 2021;15:3451–61.PubMedPubMedCentralCrossRef
23.
Xu Y, Fang R, Shao J, Cai Z. Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway. Biosci Rep 2021, 41(6).
24.
Fang T, Liu L, Liu W. Network pharmacology-based strategy for predicting therapy targets of Tripterygium Wilfordii on acute myeloid leukemia. Med (Baltim). 2020;99(50):e23546.CrossRef
25.
Zhang HQ, Xie XF, Li GM, Chen JR, Li MT, Xu X, Xiong QY, Chen GR, Yin YP, Peng F et al. Erianin inhibits human lung cancer cell growth via PI3K/Akt/mTOR pathway in vitro and in vivo. Phytother Res 2021.
26.
Canonici A, Browne AL, Ibrahim MFK, Fanning KP, Roche S, Conlon NT, O’Neill F, Meiller J, Cremona M, Morgan C, et al. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Ther Adv Med Oncol. 2020;12:1758835919897546.PubMedPubMedCentralCrossRef
27.
Hamurcu Z, Delibasi N, Gecene S, Sener EF, Donmez-Altuntas H, Ozkul Y, Canatan H, Ozpolat B. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin beta1/ src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol. 2018;144(3):415–30.PubMedCrossRef
28.
Zhu Z, Yuan J, Xu X, Wei Y, Yang B, Zhao H. Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3. Neoplasia. 2021;23(1):36–48.PubMedCrossRef
29.
Peng C, Ma W, Xia W, Zheng W. Integrated analysis of differentially expressed genes and pathways in triplenegative breast cancer. Mol Med Rep. 2017;15(3):1087–94.PubMedPubMedCentralCrossRef
30.
Huang S, Huang P, Wu H, Wang S, Liu G. Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling. Folia Histochem Cytobiol. 2021;59(4):291–301.PubMedCrossRef
31.
Kim S, Lee E, Jung J, Lee JW, Kim HJ, Kim J, Yoo HJ, Lee HJ, Chae SY, Jeon SM, et al. microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer. Oncogene. 2018;37(22):2982–91.PubMedPubMedCentralCrossRef
32.
Yang SJ, Wang DD, Zhong SL, Chen WQ, Wang FL, Zhang J, Xu WX, Xu D, Zhang Q, Li J, et al. Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637/Akt1/beta-catenin (cyclin D1) axis. Cell Death Dis. 2021;12(5):420.PubMedPubMedCentralCrossRef
33.
Liu Z, Tian Y, Chen Q, Zhang G, Li C, Luo DQ. Transcriptome Analysis of MDA-MB-231 Cells Treated with Fumosorinone isolated from insect pathogenic Fungi. Anticancer Agents Med Chem. 2020;20(4):417–28.PubMedCrossRef
34.
Sivaganesh V, Sivaganesh V, Scanlon C, Iskander A, Maher S, Le T, Peethambaran B. Protein tyrosine phosphatases: mechanisms in Cancer. Int J Mol Sci 2021, 22(23).
35.
Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metabolism. 2020;2(2):132–41.CrossRef
36.
Ghanbari F, Mader S, Philip A. Cholesterol as an endogenous ligand of ERRalpha promotes ERRalpha-Mediated Cellular Proliferation and Metabolic Target Gene expression in breast Cancer cells. Cells 2020, 9(8).
37.
Ghanbari F, Fortier AM, Park M, Philip A. Cholesterol-Induced metabolic reprogramming in breast Cancer cells is mediated via the ERRalpha Pathway. Cancers (Basel) 2021, 13(11).
38.
Qin Y, Hou Y, Liu S, Zhu P, Wan X, Zhao M, Peng M, Zeng H, Li Q, Jin T, et al. A Novel Long non-coding RNA lnc030 maintains breast Cancer stem cell stemness by stabilizing SQLE mRNA and increasing cholesterol synthesis. Adv Sci (Weinh). 2021;8(2):2002232.PubMedCrossRef
39.
Moksud N, Loo LWM, Yang J, Huang CY, Haiman CA, Le Marchand L, Wilkens LR, Cheng I. Cholesterol lowering drug use and breast cancer survival: the multiethnic cohort study. Breast Cancer Res Treat. 2021;190(1):165–73.PubMedPubMedCentralCrossRef
40.
Mansourian M, Haghjooy-Javanmard S, Eshraghi A, Vaseghi G, Hayatshahi A, Thomas J. Statins use and risk of breast Cancer recurrence and death: a systematic review and Meta-analysis of Observational studies. J Pharm Pharm Sci. 2016;19(1):72–81.PubMedCrossRef
41.
Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29(12):1592–8.CrossRef
42.
Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol. 2012;12(6):677–82.PubMedCrossRef
43.
Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094–8.PubMedPubMedCentralCrossRef
44.
Qiu T, Cao J, Chen W, Wang J, Wang Y, Zhao L, Liu M, He L, Wu G, Li H, et al. 24-Dehydrocholesterol reductase promotes the growth of breast cancer stem-like cells through the hedgehog pathway. Cancer Sci. 2020;111(10):3653–64.PubMedPubMedCentralCrossRef
45.
Kasahara K, Nakayama Y, Sato I, Ikeda K, Hoshino M, Endo T, Yamaguchi N. Role of src-family kinases in formation and trafficking of macropinosomes. J Cell Physiol. 2007;211(1):220–32.PubMedCrossRef
46.
Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, Colin S, Vallez E, Lestavel S, Lefebvre P, et al. The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis. 2016;249:200–8.PubMedCrossRef
47.
McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, Liew FY, Ramji DP. IL-33 reduces macrophage foam cell formation. J Immunol. 2010;185(2):1222–9.PubMedCrossRef
48.
Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, Zou Z, Li P, Guo Q, Ma L, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12(1):177.PubMedPubMedCentralCrossRef
49.
Yun UJ, Lee JH, Shim J, Yoon K, Goh SH, Yi EH, Ye SK, Lee JS, Lee H, Park J, et al. Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. Lab Invest. 2019;99(8):1157–72.PubMedCrossRef
Metadata
Title
Erianin inhibits the progression of triple-negative breast cancer by suppressing SRC-mediated cholesterol metabolism
Authors
Ming Li
Shiyao Kang
Xuming Deng
Huimin Li
Yuan Zhao
Wenru Tang
Miaomiao Sheng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03332-2

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance

Research

PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model

Research

Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma

Research

Sparassis latifolia and exercise training as complementary medicine mitigated the 5-fluorouracil potent side effects in mice with colorectal cancer: bioinformatics approaches, novel monitoring pathological metrics, screening signatures, and innovative management tactic

Research

PD-L1 intrinsically promotes the proliferation of breast cancer cells through the SKP2-p27/p21 axis

Research

Novel lncRNAs LINC01221, RP11-472G21.2 and CRNDE are markers of differential expression in pediatric patients with T cell acute lymphoblastic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits